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REGULATION OF RECEPTOR TYROSINE KINASES BY UBIQUILIN1 
Zimple Kurlawala 
June 25, 2015 
Receptor Tyrosine Kinases (RTK’s) like EGFR, Insulin Receptor, IGF1R and 
others mediate growth, proliferation and balance between apoptosis and survival. 
Dysregulation of RTK activity has been identified in a wide range of cancers and 
contributes to initiation, progression and metastasis of tumors. Ubiquilins 
(UBQLN) are fairly novel proteins and are studied mostly in the field of 
neurodegenerative disorders. Our laboratory recently discovered a link between 
UBQLN1 function and tumorigenesis. UBQLN1 is lost in about 50% of non-small 
cell lung cancer (NSCLC) cases. We have identified an interaction between 
UBQLN1 and IGF1R. Furthermore, UBQLN1 regulates activity of IGF1R and 
EGFR. Following loss of UBQLN1 in lung adenocarcinoma cells, there is 
decreased expression of IGF1R and EGFR at the mRNA and protein levels. 
Fewer receptors are available for ligand binding on plasma membrane of 
UBQLN1 deficient cells. Despite this decrease in total number of receptors, the 
ratio of active:inactive (phosphorylated:non-phosphorylated) receptor is higher in 
cells that have loss of UBQLN1 function. We conclude that UBQLN1 is essential 
in normal regulation of RTKs. Loss of UBQLN1 leads to persistent stimulation of 
IGF1R and EGFR which may contribute to transforming events in UBQLN1 
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deficient cells. Understanding the role of UBQLN1 in regulating receptor tyrosine 
kinase activity can facilitate development of pharmacological drugs targeting 
novel pathways in diseases that have altered function of UBQLN1.
vi 
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CHAPTER 1: INTRODUCTION 
 
Ubiquilins (PLICs) 
The Ubiquilin family of proteins (UBQLN1-4, UBQLNL) are evolutionarily 
conserved and structurally similar to each other. These proteins are encoded by 
genes on different chromosomes: UBQLN1 (9q22, 589 or 561 amino acids), 
UBQLN2 (Xp11.21, 624 amino acids), UBQLN3 (11p15, 654 amino acids), 
UBQLN4 (1q21, 601 amino acids) and UBQLN-L (11p15.4, 475 amino acids) [1]. 
Ubiquilins are also known as Proteins Linking IAP with Cytoskeleton (PLICs) as 
these were originally discovered as proteins that anchor vimentin filaments to the 
plasma membrane through 
interaction with CD47, an 
integrin-associated protein 
(IAP) [2]. UBQLN1 is 
approximately 63 kDa protein 
and all its family members 
have 3 main domains: 
ubiquitin-like domain (UBL) at 
the N-terminus, ubiquitin-
associated domain (UBA) at 
the C-terminus and STI chaperone-like regions in the middle (Figure 1). UBQLN1 
 
Figure 1: Schematic of structural domains 
of UBQLN1 
UBL domain: UBiquitin-Like domain interacts 
with the S5a cap of the proteasome. 
STI-1,2,3,4 domains: STress-Inducible 
proteins. These domains act as chaperonins 
that mediate protein-protein interactions. 
UBA domain: UBiquitin-Associated domain 




maintains all the functionally important motifs present in this group [3]. 
Expression of Ubiquilin varies based on tissue type.  UBQLN1 is ubiquitously 
expressed in all tissues, UBQLN2 and UBQLN4 show relatively higher 
expression in the brain, spleen, heart, liver and pancreas over other tissues, 
UBQLN3 is exclusively expressed in the testis [3] and UBQLNL is mostly found in 
plasma, platelet and liver. 
 
Proposed  Functions 
Owing to their structural orientation, Ubiquilins are categorized as ubiquitin 
binding proteins (UBPs). UBQLN1 assists in proteasomal degradation of 
ubiquitinated substrates and also participates in ERAD (Endoplasmic Reticulum 
Associated Degradation), autophagy, apoptosis and receptor trafficking [4]. The 
UBL domain of UBQLN is structurally similar to ubiquitin and interacts with the 
proteasomal cap (S5a) [5] while the UBA domain associates directly with 
ubiquitin [6, 7]. The central region consisting of STI domains are called so 
because of their similarity to STI-1 proteins (STress Inducible proteins or Hsp70-
Hsp90 organizing protein, HOP). This region acts as a co-chaperone and 
mediates hydrophobic interactions with other proteins [8, 9]. Together, the UBL 
domain of Ubiquilin1 binds to the proteasome while the UBA domain binds to 
ubiquitin on the substrate protein and aids in the substrate’s degradation [5].   
 
Several studies have reported that UBQLN1 facilitates proteolysis of substrates 
that it binds to. Dsk2p, the yeast homolog of UBQLN1, forms a trimeric complex 
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with Rad23p and Cdc48 and enables degradation of misfolded proteins via the 
proteasomal system [10]. In human cells, the UBL domain of UBQLN1 has been 
shown to regulate degradation of misfolded proteins like Ataxin3, HSJ1a and 
EPS15 [11]. UBQLN1 expression aids in poly-ubiquitination of viral polymerase 
NS5B, decreasing its half-life in HCV infected hepatocytes [12]. In contrast, 
UBQLN1 stabilizes proteins like Presenilin1 and 2 [3, 13], Rad23 [14], IκB [15], 
and Bclb [1] when bound to them.  
UBQLN1 and UBQLN2 were originally (1999) identified in ovarian cancer cells 
and showed to increase cell spreading and integrin mediated interactions with 
the extracellular matrix. Identifying functions of Ubiquilin proteins is an ongoing 
area of research. UBQLN1 is a stress-response protein; its expression protects 
astrocytes from hypoxia [16] and HeLa cells from starvation-induced death [17]. 
In 2010, Rothenberg et al showed that UBQLN1 interacts with autophagy marker 
LC3 in a complex with other proteins and reduction in UBQLN1 expression 
decreases autophagy levels in HeLa cells, brain and liver tissue of mice [18]. 
UBQLN1 is also reported to interact with the metabolite mTOR; however, the 
consequences of this interaction are not known [19]. In superior cervical ganglion 
neurons, UBQLN1 expression limits the expression of unassembled nicotinic 







Ubiquilin in Neurodegenerative Disorders 
Presenilin proteins (PS1 and 2) are well-established Alzheimer’s disease-
associated proteins [21]. UBQLN1 binds to and stabilizes PS1 and 2 and co-
localize in a vesicular-like or ER-like pattern [3, 12]. A meta-analysis in 2014 
confirmed that a single intronic C/T polymorphism in UBQLN1 (UBQ-8i) 
significantly increased risk of Alzheimer’s disease [22, 23]. In the presence of this 
polymorphism, the STI domains of UBQLN1 are unable to bind to PS proteins as 
a result of which a gamma secretase complex is formed generating Aβ40 and 
Aβ42 amyloid aggregations [13, 24, 25]. Ford et al (2006) hypothesize that UBQ-
8i polymorphism favors formation of UBQLN dimers and loses its ability to bind to 
PS proteins. Neurofibrillary tangles and Lewy bodies in brains of Alzheimer’s 
disease and Parkinson’s patients robustly stained for anti-UBQLN antibodies 
provide more evidence to the role of UBQLN in these diseases [13]. 
UBQLN1 is also implicated in pathogenesis of triplet repeat neurodegenerative 
diseases especially ones characterized by expanded polyglutamine (PolyQ) 
tracts. Of the nine different types of PolyQ diseases, UBQLN1 plays a role in 
Huntington’s disease (HD) and spinocerebellar ataxia type1 [26]. The expansion 
of glutamine tracts leads to aggregation of the affected protein as it is unable to 
get degraded effectively in absence of UBQLN1. In an animal model of 
Huntington’s disease, UBQLN4 expression was identified to be protective as it 
decreased polyQ-induced protein aggregation though its interaction with Ataxin1 
and UBQLN1 [27]. 
5 
 
UBQLN2 mutations have been identified in X-linked Amyotropic Lateral Sclerosis 
(ALS) and Fronto-Temporal Dementia (FTD). UBQLN2-positive inclusions are 
detected in spinal cord of ALS patients and in hippocampus of ALS patients with 
dementia proposing a role of mutant UBQLN2 aggregation in neurodegeneration 
[28]. 
Ubiquilin in Cancer 
First evidence of role of Ubiquilin proteins in cancer development was reported in 
1999, when Funakoshi and colleagues found that XDRP1, a Xenopus orthologue 
60% similar to Ubiquilin1 interacted with cyclin A, preventing its degradation and 
arresting cell division. Another way UBQLN1 has been proposed to regulate cell 
division is by binding to a tumor suppressor protein DAN and S(1-5) which 
modulates DNA synthesis. In contrast, UBQLN2 expression enhanced tumor 
progression in osteosarcoma [29]. 
Previous work from our lab has identified UBQLN1 as a regulator of anti-
apoptotic protein Bcl2L10/Bclb [1]. We have reported that UBQLN1 is lost in 
about 50% of lung adenocarcinomas and tissue samples have varying UBQLN1 
mRNA levels. We have also shown that loss of UBQLN1 or UBQLN2 promotes 








Kinases (RTK’s)  
Receptor Tyrosine 
Kinases are cell surface 
proteins that have an N-
terminus extracellular 
domain, a transmembrane 
domain and a C-terminus 
intracellular domain 
possessing intrinsic 
tyrosine kinase activity 
(Figure 2). These 
receptors are present on the cell surface as preformed dimers as in case of 
Insulin-like Growth Factor 1 Receptor (IGF1R) or undergo dimerization upon 
ligand binding for example Epidermal Growth Factor Receptor (EGFR). There 
are approximately thirteen subfamilies of RTK’s and sixty members in all [30]. 
Receptor activation occurs upon binding to specific ligands, following which the 
receptor gets auto- and trans-phosphorylated at their intracellular domain and 
stimulates downstream signaling pathways that mediate growth, proliferation, 
survival, tissue homeostasis, and metabolism. Dysregulation of RTK’s have been 
identified in a number of cancers and can be responsible for initiation, 
progression and metastasis of tumors. Receptor tyrosine kinases like EGFR, 
IGF1R, Insulin receptor (INSR), FGFR and non receptor tyrosine kinases like 
 
Figure 2: Schematic of structural domains of 
IGF1R Receptor tyrosine kinases have an 
extracellular domain that binds to and is activated 
by ligand, a transmembrane domain spanning 
across the plasma membrane and an intracellular 
domain bearing multiple tyrosine residues that 
undergo auto- and trans- phosphorylation. The 
above schematic is of the receptor tyrosine kinase 
IGF1R that is present on the plasma membrane 
as a preformed homodimer held together by 
disulfide bonds as shown. Each part of the dimer 
consists of the α and β subunits. 
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SRC, Abl, FAK are upregulated in a wide range of cancers [31]. In normal cells, 
the activity of RTK’s is tightly regulated. However, these can become oncogenic 
following gain of function mutations, gene rearrangement, gene amplification, 
loss of genomic imprinting or abnormal receptor or ligand activation. RTKs like 
EGFR and analogues HER2, Erb2; VEGF and VEGFR, IGF1R and others are 
major targets of current cancer therapies. 
 
EGFR and IGF1R 
The epidermal growth factor receptor family comprises of many subtypes of 
receptors: EGFR (ErbB1), ErbB2/HER2/neu, ErbB3/HER3 and ErbB4/HER4. 
Ligands of these receptors include EGF, amphiregulin, betacellulin, neuregulins, 
and others.Activation of EGFR stimulates growth and proliferative pathways. 
Mutations and overexpression of EGFR family of proteins are largely implicated 
in lung adenocarcinoma and breast cancers [32]. 
 
Insulin-like growth factor 1 receptor (IGF1R), IGF2R and IR (insulin receptor) are 
RTKs that are ubiquitously expressed in cells and bind to their ligands IGF1, 
IGF2, insulin with differing affinities. Their basic function is to stimulate growth 
and survival. IGFBPs (IGF binding proteins 1-6) also bind these ligands and limit 
their bioavailability to bind to RTKs [33]. Increased IGF1R expression is found in 
a number of cancers, including breast, prostate, colorectal, liver, lung and 
melanoma. In a study by Nakagawa et al in 2012, IGF1R expression was 
associated with an increased risk of recurrence of non-small cell lung cancer 
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(NSCLC). A meta-analysis of 17 studies comprising 3,294 NSCLC patients 
concluded that IGF1R expression positively correlated with smoking status, 
tumor size and is a negatively correlated with disease free survival [34]. 
Increased IGF1 levels increase the risk of development of breast, prostate, 
colorectal cancers. Normally, cells are dependent on circulating levels of IGF1 
produced by the liver but cancer cells show increased IGF1R activity by 
producing their own IGF1 through autocrine and paracrine processes. IGF1R 
activation stimulates PI3K/AKT (survival) and RAS/MAPK (proliferation) 
pathways [35].  
 
IGF1R Structure and Trafficking IGF1R is synthesized as a monomer 
consisting of α and β chains. This monomeric pro-receptor undergoes maturation 
though proteolysis and glycosylation to form dimers. IGF1 receptors are present 
on the the cell surface as preformed dimers unlike EGFR that form dimers upon 
ligand binding (Figure 3). The β subunit consists of 627 amino acids, has a small 
extracellular portion, transmembrane portion and the intracellular C-terminal. The 
juxtamembranous region in the β subunit hosts the NPXY motif and the catalytic 
region. The NPXY motif participates in the process of receptor internalization 
while the catalytic region is crucial for ATP binding. Tyrosine 1131, 1135 and 
1136 in the intracellular tyrosine kinase domains are critical for receptor 
autophosphorylation. The intracellular domains hold crucial signals that decide 
the fate of receptor trafficking once it is activated. For example, even though 
overall there is 70% amino acid homology between IGF1R and Insulin receptor, 
there is only 44% homology in their C-terminus sequence which dictates the 
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differences in downstream signaling pathways and functions between the 2 
receptors. The NPXY motif recognizes the phosphotyrosine binding domains  
(PTB) of IRS proteins and SH2 proteins (Figure 4). The IRS proteins (IRS 1-4) 
undergo full activation within 1-2 mins and Shc protein within 5-10 mins of ligand 





Figure 3: IGF-1R structure–function relationship. Adapted from Girnita et al, 
2014. This map depicts location of amino acid residues in IGF1R and their functions, 






IRS proteins interact with IGF1R on the cell surface through their pleckstrin 
homology domains (PH) and PTB domains are present in their N-terminus. The 
C-terminus region of IRS proteins are variable and control the variety of 
interactions with other signaling molecules. The C-terminal of IRS proteins have 
a high affinity for proteins that have an SH2 domain like PI3K, Grb2, SH-PTP2  
(phosphatase), adaptor proteins like CRK, NCK1 which act as  docking proteins 
for interaction of IGF1R with other proteins like β1 integrins on the cell surface. 
Like IRS proteins, 
SHC proteins (SHC 
A-D) also consist of 
a PTB domain  at 
their N-terminal and 
a SH2 domain at 
their C-terminal an
interact with 




the interactions they are capable of control further trafficking events of the 
activated receptor. Internalization of IGF1R is known to occur through clathrin 
mediated endocytosis (CME) and also through calveolin mediated endocytosis at  
high levels of IGF1 [37]. Internalized RTK’s in early endosomes proceed to late 
 
 
Figure 4: IGF1R signaling pathways. Adapted from 
Girnita et al, 2014. Upon activation by ligand IGF1, there is 
phosphorylation of intracellular tyrosine kinase domains of 
IGF1R.  The activated receptor phosphorylates IRS and 
Shc proteins as its first substrates, which further activate 
other proteins like GRB2, SOS and so on. Broadly, IGF1R 
leads to activation of 2 major kinase cascades - RAS/MAPK 





continue to send 
signals through their C-
terminus in the 
cytoplasm. In the late 
endosome, the RTK 
either gets recycled 
back to the plasma 
membrane through a 
recycling endosome or 
gets degraded via 
lysosomal or 
proteasomal pathways 
(Figure 5). Multi-protein 
complexes called 
Endosomal Sorting Complex Required for Transport (ESCRT) are critical for 
cellular transport of activated receptors [37]. These processes occur by 
systematic co-operation of a variety of adaptor proteins and in absence of an 
interacting partner can potentially disturb trafficking and alter biological 
consequences. Ubiquitin interacting motif (UIM) containing adaptor proteins like 
Epsin, Eps15, Eps15R recognize ubiquitin on RTKs, bind to clathrin and AP2 
simultaneously and are critical for clathrin mediated endocytosis (CME) of some 
RTKs like EGFR (Figure 6). The NPXY motif not only regulates internalization of 
 
 
Figure 5: Endocytic Trafficking of RTK 
Adapted from Goh & Sorkin [37]. This figure shows 
2 pathways of endocytosis of ligand bound RTK: 
clathrin mediated and calveolin mediated. The 
internalized receptor in clathrin-coated vesicles 
(CCV) is transported to the early endosome (EE) to 
the sorting endosome (SE) or the mutivescicular 
body (MVB) and from here either to the recycle 
endosome to be recycled back to the plasma 




IGF1R but also its 
downregulation. All RTKs 
possess a ubiquitin 
binding motif and 
ubiquitination has been 
well established as a 
crucial regulatory process 
of RTK trafficking. 
Ubiquitin is a small protein 
(7 kD) that is added to 
IGF1R in 3 consecutive 
steps via the E1, E2 and 
E3 ligases. The first two 
enzymes, E1 and E2 work to load the last enzyme E3 on to IGF1R to add 
ubiquitin molecules on the receptor. IGF1R is a known substrate of three E3 
ligases:  Mdm2 [38]  Nedd4 [39] and c-Cbl [40].  Ubiquitination of IGF1R occurs 
before entering the endocytic vessels during internailization [39]. Mdm2 poly-
ubiquitinates IGF1R with K63-type chains and β-arrestins have been identified as 
crucial adaptor proteins to recruit Mdm2 to IGF1R [41]. Similarly, Grb10 is a key 
adaptor protein that recruits Nedd4 to IGF1R which  multi mono-ubiquitnates the 
receptor [39]. At higher doses of IGF1, c-Cbl poly-ubiquitinates IGF1R with K48-
type chains. Mdm2 recruitment favors stimulation  of MAPK over PI3K pathways. 
Like IGF1R, EGFR is also poly-ubiquitinated with K63-type chains [42]. K48 poly-
 
Figure 6: Schematic of clathrin mediated 
endocytosis of EGFR. Adapted from Madshus et al 
[38].  Phosphorylated RTK and activates tyrosine 
kinases facilitating binding of an E3 ligase Cbl to 
the C-terminal of the RTK, or indirectly via an 
adaptor protein Grb2. Poly-Ub chains added by 
Cbl interact with Ub-interaction motifs (UIMs) of 
Epsin-1 and Eps15 which act in co-ordination 
with other proteins (not shown) and subsequently 
cause invagination of the plasma membrane and 




ubiquitination signals target substrates for proteasomal degradation while K63 
mono- and poly-ubiquitination are recognized by other proteins through their 
ubiquitin binding domains (UBD) and activate enzyme cascades like kinases, 
phosphatases, phospholipases and so on that feed into and activate multiple 
downstream pathways like PI3K/AKT, RAS/MAPK, metabolic pathways and 
others [43, 44]. Ubiquitination is a major molecular signal responsible for 
endocytic sorting such that ubiquitination of IGF1R is essential for its 
internalization while its not for other RTKs like EGFR and FGFR2. However, 
degradation of these 3 RTK’s is highly dependent on their ubiquitin-conjugation 
[42, 45, 46].  
 
Aim 










CHAPTER 2: MATERIALS AND METHODS 
 
Cell culture 
Human normal lung epithelial cell line HPL1D and human non-small cell lung 
carcinoma cell line A549 and H358 were purchased from American Type Culture 
Collection (ATCC, Rockville, MD, USA) and cultured in RPMI medium 
supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and 
1% antibiotic/antimycotic (Sigma, St Louis, MO, USA). The 3 cell lines were 
routinely subcultured every 3–4 days. All siRNA transfections were performed 
using Dharmafect1 #T-2001-03 (Thermo Fisher Scientific Inc, Pittsburgh, PA, 
USA) as per manufacturer’s protocol. After total 48 hours of transfection, cells 
were serum starved for 12 hours. After which IGF1 50ng/ml or 10ng/ml of EGF 
was added to stimulate the cells. For protein stability studies, 20uM of 
Cycloheximide was added an hour prior to adding IGF1. MG132 (25uM) and 
NH4Cl (20uM) were also added an hour prior to adding IGF1 for experiments 
investigating route of degradation of RTKs. At the end of stimulation, 6 hours for 
IGF1 and 3 hours for EGF, cells were harvested in CHAPS lysis buffer (1% 
CHAPS detergent, 150mM NaCl, 50mM Tris pH 7, 5mM EDTA). Protein was 
quantitated by using Pierce's BCA Protein Assay Reagent Kit (# 23227) from 




Immunoprecipitation and Western Blot Analysis 
293T cells were cultured in DMEM supplemented with 10% FBS. DNA 
transfections were done using PEI (PEI 2.5:1 DNA).  All cell extracts were 
prepared following scrape harvesting of 293T cells using CHAPS lysis buffer (1% 
CHAPS detergent, 150 mM NaCl, 50 mM Tris pH 7, 5 mM EDTA), For 
immunoprecipitations, 200 ug of protein was incubated in 400 uL of total CHAPS 
buffer and incubated with indicated affinity matrix (Anti-FLAG beads) for 1 h at 
4 °C. Following incubation, the matrix was washed three times in CHAPS buffer 
and then SDS loading buffer was added directly to washed matrix, boiled, and 
loaded directly into the wells of a PAGE gel. Drug treatments were performed as 




Cells were dry seeded in 35 mm IF plates culture and transfected with either non 
targeting siRNA (siNT) or with siRNAs targeting UBQLN1 (siU1 and siU1-2) the 
following day. After 48 hrs of transfection, cells were fixed with 4.0% 
paraformaldehyde in PBS for 15-20 min and then permeabilized with 0.1% 
Saponin for 60 minutes at room temperature. Cells were rinsed thrice with PBS, 
and then incubated overnight with anti-UBQLN1 or anti-IGF1R antibody (at a 
dilution of 1:1000). Next day, after three successive washes with PBS, cells were 
then incubated with Alexa Fluor 488 goat anti-rabbit IgG (A11034: Molecular 
Probes, Invitrogen detection technologies, Eugene, OR, USA) at a dilution of 
16 
 
1:1000. After incubation with secondary antibody for 60 minutes, cells were 
rinsed with PBS and incubated with Alexa Fluor 568 Phalloidin (A12380: Life 
technologies Eugene, OR, USA) for 10 minutes at the dilution of 1:1000. After 3 
successive washes with PBS, nuclei were counterstained with DAPI (diluted 
1:000) for 10 min at room temperature followed by three washes (5–10 min each) 
with PBS. The cells were then imaged under Nikon A1R confocal laser scanning 
microscope. Multiple images were acquired from multiple experiments and 
representative images are presented. 
 
Radioligand Binding 
Cells were incubated for 2 hours with increasing concentrations (0.001 nM to 
0.05 nM) of 125I-IGF1 (Perkin Elmer, Waltham, MA) at 4°C in binding buffer 
(DMEM/20 mM HEPES/0.1% BSA, pH 7.3). Two fractions were collected – total 
ligand binding (125I-IGF1) and non-specific binding (mixture of radiolabeled and 
non-radiolabeled ligand). After 2 hours incubation on ice, cells were washed four 
times with binding buffer to remove unbound radioligand. Solubilizing buffer 
(0.5N SDS, 1N NaCl) was used to collect the cells and the radioactivity of each 
fraction was determined using a Beckman Coulter (Brea, CA) gamma counter. 
Specific binding for each concentration of 125I-IGF1 was calculated by subtracting 
non-specific binding from total binding for that concentration of 125I-IGF1. 





Total RNA Extraction and Real Time PCR 
Total RNA was isolated from the A549 cells after washing twice with phosphate-
buffered saline (PBS) and harvested with E.Z.N.A Total RNA Extraction Kit 
(Omega, USA) according to the supplier’s protocol followed by DNAse digestion. 
RNA quality and quantity were determined by photometry. Total RNA (1μg) was 
reverse-transcribed to cDNA using Thermo Script RT–PCR kit. Briefly, RNA was 
reverse-transcribed in cDNA with oligo (dT) primers and 200 U of Superscript II 
(Invitrogen) following manufacturer’s instructions. Real-time analysis for IGF1R, 
EGFR, and normalizing gene human β2Microglobulin was performed using 
SYBR Green Master Mix as per the manufacturer’s instruction (Applied 
Biosytems). This technique continuously monitors the cycle-by-cycle 
accumulation of fluorescently labeled PCR product. Briefly, cDNA corresponding 
to 25 ng of RNA served as a template in a 10μl reaction mixture containing, 
0.2 nM (each) primer, and 5 μl FastStart DNA Master SYBR Green mix (ABI). 
Samples were loaded into 96-well plate format and incubated in the fluorescence 
thermocycler 7500 (ABI System). Initial denaturation at 95 °C for 10 min was 
followed by 45 cycles, each cycle consisting of 95 °C for 15 s, touchdown of 
1 °C/cycle from the primer-specific start to end annealing temperatures for 
5 seconds, and 60 °C for 10 seconds. The primer sequences used for specific 
genes are listed in Table. All quantifications were normalized to the 
housekeeping HPRT gene, which showed a very stable expression in A549 cells. 
Fold changes in gene expression were calculated using 2−ΔΔCT method. Following 















All data were analyzed Differences between two groups were statistically 
analyzed using unpaired Student's t-test. Differences were considered significant 
when p<0.05.  
 
Reagents 
IGF1R-beta #3027, IGF1R Beta XP #9750, p-IGF1R beta #3918, EGFR #2232, 
p-EGFR #2304, AKT #9272, p-AKT #9271 (Cell Signaling Technologies Inc. 
Danvers, MA 01923); Tubulin #B512 (Sigma); GAPDH #FL335 (Santa Cruz); 
Ubiquilin polyclonal Ab was made by inoculating rabbits with a peptide specific to 
Ubqln1 (Yenzym Antibodies LLC); Alexa Fluor 488 goat anti-rabbit IgG #A11034 
(Molecular Probes, Invitrogen detection technologies, Eugene, OR. USA); Alexa 
Fluor 568 Phalloidin #A12380 (Life technologies Eugene, OR. USA); Anti-FLAG 







RNAi Sequences  
All RNAi (siRNAs) used for study were ordered from Thermo Fisher Scientific 
Biosciences Inc. Lafayette, CO 80026, USA and transfections were done using 
Dharmafect1 as per the suppliers instructions. 
NonTargeting siNT UAAGGCUAUGAAGAGAUACAA 
Ubiquilin1 siUBQLN1 GAAGAAAUCUCUAAACGUUUUUU 
 siUBQLN1-2 GUACUACUGCGCCAAAUUU 
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CHAPTER 3: RESULTS 
UBQLN1 is lost and under-expressed in cancers (Previous work) (Figure 7) 
Previously, our lab has shown that UBQLN1 is lost, mutated and under -
expressed in human cancers. We analyzed 877 cancer cell lines from 
the Cancer Cell Line Encyclopedia and found that 243 (27.7%) had loss 
or deletion of UBQLN1. Furthermore, these cancer cell lines 
demonstrated significantly lower expression of UBQLN1 (P<0.0001) 
than those without loss or deletion suggesting that copy number 
alteration is a mechanism of UBQLN1 inactivation in cancer cells. 
Similarly, examination of 230 lung adenocarcinoma tumors from the 
Cancer Genome Atlas revealed a high frequency of copy number loss 
(50.8%) with a corresponding significant decrease in gene expression 
levels (P<0.001)[4]. Our lab has identified 343 genes by microarray 
analyses that are expressed differently between tumors with h igh or 
low levels of UBQLN1. By Ingenuity pathway analysis, we found that 
UBQLN1 played a major role in proteins associated with molecular 
transport and protein trafficking. Among these are  proteins involved in 
signaling pathways like MYC and AKT signaling and other proteins 











Figure 7: Ubiquilin1 is lost and under-expressed in cancers [4]  
 
UBQLN1 is frequently lost and under-expressed in cancer cell lines. Cancer 
cell lines are separated by UBQLN1 copy number status and their 
corresponding UBQLN1 expression plotted. Box plots depict the median 
group expression (middle line), the 25th and 75th percentiles (bottom and 
top of box, respectively), with the whiskers indicating the 10th and 90th 
percentiles. Values for all samples outside this range are represented by 
dots. The UBQLN1 locus is lost in 243 of the 877 cell lines examined. 
UBQLN1 is significantly under-expressed in samples with UBQLN1 loss or 




UBQLN1 interacts with IGF1R and INSR (Figure 8) 
To detect potential interacting partners of UBQLN1, we over-expressed FLAG 
epitope-tagged UBQLN1 followed by immunoprecipitation and mass 
spectrometry (MS) analysis to identify FLAG conjugated proteins. Interaction was 
detected for proteins ESYT1 and ESYT2 (calcium-mediated intrinsic membrane 
proteins), IGF1R, IGF2R and INSR (receptor tyrosine kinases) and BAT3/BAG6 
proteins (a cytosolic multi-protein complex involved in the post-translational 
delivery of tail-anchored membrane proteins to the endoplasmic reticulum 
membrane) (Figure 8.1, Previous Work). We confirmed the interaction 
between UBQLN1 and IGF1R by Western Blot analysis of 
immunoprecipitated FLAG-tagged UBQLN1 in HEK-293T cells in 
conditions of complete media with vehicle (DMSO), proteasomal 
inhibitor MG132 and serum starvation for 12 hours (Figure 8.2, 
Previous Work). UBQLN1 interacted with IGF1R in all 3 conditions. 
However, an increased interaction was detected when the proteasome 
was blocked with MG132. We then investigated if interaction of 
UBQLN1 with IGF1R was a phenomenon applicable to o ther receptor 
tyrosine kinases and performed similar experiments to pull down FLAG 
conjugated proteins in 293T cells and probed for other RTKs by 
Western Blot analysis. We found that insulin receptor (INSR), a protein 
60% homologous to IGF1R also interacts with UBQLN1 but EGFR 











































Figure 8.1: Immunoprecipitation/Mass Spectrometry Data 
HEK-293T cells were transfected with FLAG epitope-tagged UBQLN1 
followed by immunoprecipitation and mass spectrometry (MS) 
analysis to identify FLAG conjugated proteins. MIG is the empty 
vector used as a control for overexpression. These proteins are some 
of the top interacting partners of UBQLN1. The strongest interaction 
was detected for ESYT1, then BAT3/BAG6 and so on. Receptor 
Tyrosine Kinases IGF2R, IGF1R and INSR interact with UBQLN1. 














Figure 8.2: UBQLN1 interacts with IGF1R (Previous work) 
HEK-293T cells were transfected with either empty vector (control) or 
FLAG-epitope tagged UBQLN1 (FLAG-UBQLN1) followed by 
immunoprecipitation and Western Blot analysis to detect interaction 
between UBQLN1 and IGF1R. Post transfection, cells were cultured 
in 3 conditions: complete media with vehicle (DMSO), proteasomal 
inhibitor MG132 and serum starvation for 12 hours. UBQLN1 interacts 
with IGF1R in all 3 conditions. An increased interaction was detected 
































Figure 8.3: UBQLN1 interacts with IGF1R and INSR 
HEK-293T cells were transfected with either empty vector 
(control) or FLAG-epitope tagged UBQLN1 (FLAG-UBQLN1) 
followed by immunoprecipitation and Western Blot analysis. 
UBQLN1 interacts with IGF1R and INSR, confirming the 





Cancer Mutants of UBQLN1 may lose interaction with IGF1R (Figure 9) 
HEK-293T cells were transfected with FLAG-epitope tagged constructs of 
mutants of UBQLN1 found in lung adenocarcinomas to test for an alteration in 
ability of these mutations to interact with IGF1R (Figure 9). Eight constructs were 
chosen from different domains of wild type UBQLN1 protein. P44Q and I84F are 
mutations found in the UBL domain; Q174X, Y276D, A286T, Q433H, R313S are 
mutations found in the STI domains while R562S are mutations found in the UBA 
domain of UBQLN1. Post transfection, all mutants showed stable expression of 
the FLAG-tagged constructs. Wild type UBQLN1 interacts with IGF1R as also 
seen in previous figures, however some mutations cause a loss of this 
interaction. Mutations in the UBL domain (P44Q, I84F), UBA domain (R562S) 
and a nonsense mutation in the first STI domain (Q174X) lead to a loss of 































Figure 9: Cancer mutants of UBQLN1 lose interaction 
with IGF1R 
HEK-293T cells were transfected with FLAG-epitope 
tagged constructs of mutants of UBQLN1 followed by 
immunoprecipitation and Western Blot analysis.  P44Q and 
I84F are mutations found in the UBL domain; Q174X, 
Y276D, A286T, Q433H, R313S are mutations found in the 
STI domains while R562S mutation is found in the UBA 
domain of UBQLN1. While all transfected mutant 
constructs stably express in these cells, mutations in the 
UBL domain (P44Q, I84F), UBA domain (R562S) and a 
nonsense mutation in the first STI domain (Q174X) lead to 




UBQLN1 loss decreases IGF1R protein level expression (Figure 10) 
Following confirmation of interaction between UBQLN1 and IGF1R, steady state 
expression of IGF1R were tested in lung adenocarcinoma cell lines A549 and 
H358 and also in HPL1D lung epithelial cells. UBQLN1 protein expression was 
downregulated using 2 different siRNAs for UBQLN1 (siU1 and siU1_2) (Figure 
10).  A549 cells were cultured in 3 different conditions: complete media, serum 
starvation for 12 hours and stimulation by ligand IGF1 (6h) following 12 hours of 
serum starvation. Cycloheximide (20uM) was added to cells in all 3 conditions to 
prevent new protein synthesis. Post treatment, cells were harvested, lysed and 
analyzed by Western Blot for total and phosphorylated receptor (IGF1R or 
EGFR) expression levels. While the total IGF1R expression was decreased in 
UBQLN1 deficient cells in all 3 conditions as seen in Figure 10.1, differences 
were glaringly evident in post stimulation conditions for both receptors. 
Phosphorylated IGF1R levels were undetectable in A549 cells in complete and 
serum deficient media, however post stimulation with IGF1, the ratio of 
phosphorylated to total IGF1R levels was greatly increased in siUBQLN1 cells 
(1.46 vs. 1.05) compared to control. Results are normalized to non-treated 
control in complete media. In H358 cells exposed to conditions of serum 
starvation and IGF1 stimulation, phosphorylated/total IGF1R is higher in siU1 
cells compared to siNT cells (Figure 10.2). We detected phosphorylated IGF1R 
even in serum starved siU1 cells but absent in control. Similar results were 
















Figure 10.1: Loss of UBQLN1 decreases total IGF1R expression in 
A549 cells 
A549 cells were transfected with siRNA (NT: non targeting control, U1 
and U1_2: UBQLN1) and post transfection, cultured in 3 different 
conditions in the presence of cycloheximide (translation inhibitor): 
Complete media, Serum Starvation (SS) or stimulation with IGF1 for 6 
hours, post 12 hours of serum starvation. Total IGF1R levels were 
decreased in UBQLN1 knock down cells and results are more 
pronounced post stimulation with IGF1. Phosphorylated IGF1R levels 
were undetectable in A549 cells in complete and serum deficient 
media, however post stimulation with IGF1, the ratio of phosphorylated 
to total IGF1R levels was greatly increased in siUBQLN1 cells (1.46, 













Figure 10.2: Loss of UBQLN1 decreases total IGF1R expression in H358 
and HPL1D cells 
H358 cells were transfected with siRNA (NT: non targeting control, U1: 
UBQLN1) and post transfection, cultured in 2 different conditions in the 
presence of cycloheximide (translation inhibitor): Serum Starvation (SS) or 
stimulation with IGF1 for 6 hours, post 12 hours of serum starvation. Total 
IGF1R levels were decreased in UBQLN1 knock down cells. There is 
increased expression of phosphorylated IGF1R in UBQLN1 knock down 
cells in serum starved cells as well as post stimulation with IGF1. Similarly, 
in lung epithelial cell line HPL1D, following siRNA transfection, total receptor 






Loss of UBQLN1 results in decreased cell surface expression of IGF1R 
(Figure 11) 
Following Western Blot data that showed decreased total IGF1R expression in 
cells, saturation binding assays were performed to test if the overall decrease in 
total IGF1R expression also reflected as a decrease in receptor number on the 
cell surface. Radioligand binding assays were performed utilizing radioactive 
ligand (I125-IGF1) to test for differences in the number of binding sites (number of 
cell surface receptors) in HPL1D cells between UBQLN1 deficient cells and 
control (Figure 9). In these experiments, HPL1D cells were transfected with 
UBQLN1 siRNA (siU1) or control (siNT) and 48 hours post-transfection, cells 
were incubated with increasing concentrations of the radiolabeled ligand (I125-
IGF1) with the intention to saturate the receptors. The purpose of performing 
saturation binding assays was to determine the differences in maximum binding 
capacity Bmax (number of cell surface receptors) between UBQLN1 deficient cells 
and control. Plotting saturation curves showed that although the amount of 
radioactive ligand used did not saturate the receptors, the total binding activities 
for I125-IGF1 were considerably lower in cells with loss of UBQLN1 compared to 
control (Figures 11.1). Scatchard plot analysis suggests that IGF1 receptors 
exhibit properties of positive cooperativity i.e. binding of ligand to one site 
increases the affinity at other binding sites. Overall, Bmax or number of cell 
surface IGF1 receptors was 2-fold lower in UBQLN1 deficient cells while the Kd 
i.e. affinity is almost the same (0.4 x 10
-10 
M vs. 0.6 x 10
-10 
M) (Figure 11.2). Data 
























Figure 11.1: Saturation binding of I125-IGF1 in HPL1D cells 
HPL1D cells were transfected with UBQLN1 siRNA (siU1) or control 
(siNT) and 48 hours post-transfection, cells were incubated with 7 
increasing concentrations of the radiolabeled ligand I125-IGF1 (counts per 
minute, CPM added) and cells were processed after 2-hour incubation to 
determine the amount of radioligand bound to the cell surface receptors 
(CPM bound). Plotting saturation curves showed that the total binding 
activities for I125-IGF1 were considerably lower in cells with loss of 
UBQLN1 (siU1) compared to control (siNT). Total: Total binding of I125-
IGF1 to cell surface proteins. Non-Specific: Binding of I125-IGF1 to cell 
surface proteins other than IGF1R. Specific: Binding of I125-IGF1 to 
IGF1R and is calculated by subtracting Non-Specific CPM from Total 
CPM for each dose of I125-IGF1. Radioactivity was measured as CPM in 
a Beckman gamma counter (efficiency=0.45). Specific activity of I125-












receptors/cell 2.54 x 10
7 
receptors/cell 
23 fmol/mg total protein 11 fmol/mg total protein 
Kd 0.6 x 10
-10 




Figure 11.2: Scatchard plot analysis  
Scatchard plots were graphed using binding data to determine the number 
of ligand-binding sites (Bmax) on the cell surface and to calculate ligand 
affinity (Kd) for IGF1R. Data are plotted as bound receptors versus 
bound/free receptors. Scatchard plot for IGF1R exhibits positive 
cooperativity for I125-IGF1. The table represents the differences in Bmax in 
HPL1D cells that have loss of UBQLN1. There were fewer binding sites on 
surface of UBQLN1 deficient cells while the Kd remained constant. 
Radioactivity was measured as counts per minute (CPM) in a Beckman 
gamma counter (efficiency=0.45). Specific activity of I125-IGF1 = 2200 
Ci/mmol. 
 


































Immunofluorescence (Figure 12) 
Confocal microscopy imaging was performed to test for any gross detectable 
changes in overall expression of IGF1R between UBQLN1 deficient cells and 
control. Figure 12.1 demonstrates confirmation of UBQLN1 knock down using 
siU1 in HPL1D cells. HPL1D, A549 and H358 cells were transfected with siRNA 
(siUBQLN1 and siNT) and 48 hours post-transfection, cells were fixed and 
permeabilized and probed with indirect fluorescence targeting β-IGF1R in these 
cells. Overall, IGF1R expression was higher in lung adenocarcinoma cell lines 
A549 and H358 (Figure 12.3) compared to lung epithelial cell line HPL1D (Figure 
12.2). In HPL1D cells, we observed slight decrease in cell surface expression of 

















Figure 3: Immunofluorescence imaging of UBQLN1 
 
 
Figure 12.1: Confocal microscopy image of UBQLN1 
Cells were incubated overnight in complete media at 4C with primary 
antibody against UBQLN1. Alexa 488- conjugated secondary antibody was 
used for indirect fluorescence detection. DRAQ5 was used to stain nuclei 
and Phalloidin was used for staining of cytoskeletal β-Actin. HPL1D cells 
with siRNA against UBQLN1 clearly show a decreased signal for UBQLN1 
staining. The images were captured using Nikon A1R confocal microscope. 







Figure 12.2: Immunofluorescence imaging of β-IGF1R in lung epithelial 
cell line. 
Cells were incubated overnight in complete media at 4C with primary 
antibody against β-IGF1R. Alexa 488- conjugated secondary antibody was 
used for indirect fluorescence detection. DRAQ5 was used to stain nuclei and 
Phalloidin was used for staining of cytoskeletal β-Actin. In HPL1D cells, there 
clearly appears to be lower expression of IGF1R on the plasma membrane of 
cells that have loss of UBQLN1 (siU1) compared to control. The images were 











Figure 12.3: Immunofluorescence imaging of β-IGF1R in hLAC cell 
lines. 
Cells were incubated overnight in complete media at 4C with primary 
antibody against β-IGF1R. Alexa 488- conjugated secondary antibody was 
used for indirect fluorescence detection. DRAQ5 was used to stain nuclei 
and Phalloidin was used for staining of cytoskeletal β-Actin. Overall, there is 
higher expression of IGF1R in hLAC cells (A549, H358) than lung epithelial 
cells (HPL1D) but there are no grossly detectable differences in its 
expression in UBQLN1 deficient cells (siU1). The images were captured 
using Nikon A1R confocal microscope. The scale represents 20µM. 
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Loss UBQLN1 leads to decreased IGF1R and EGFR mRNA levels in 
A549 cells (Figure 13) 
Quantitative real-time PCR (qRT-PCR) were performed in A549 cells to 
test for relative mRNA levels of IGF1R and EGFR in cells that have 
siRNA mediated loss of UBQLN1 (Figure 13). Results were normalized 
to housekeeping gene human beta-2-microglobulin. We found a 2-fold 
decrease in IGF1R mRNA levels (p=0.0015, SEM=0.04 for siUBQLN1, 
p=0.0094, SEM=0.06 for siUBQLN1-2) and almost 30% decrease in 
EGFR mRNA levels (p=0.0261, SEM=0.08 for siUBQLN1) in UBQLN1 
deficient cells. Data are representative of 3 independent experiments 































































Figure 13: Relative mRNA levels of IGF1R and EGFR in 
A549 cells 
A549 cells were transfected with siRNA (siNT: control, siU1, 
siU1_2: UBQLN1) and cultured in complete media. 48 hours 
post transfection, qRT-PCR was performed. A 50% decrease in 
IGF1R mRNA levels (*p=0.0015, SEM=0.04 for siUBQLN1 , 
#p=0.0094, SEM=0.06 for siUBQLN1-2) and almost 30% 
decrease in EGFR mRNA levels (*p=0.0261, SEM=0.08 for 




Loss of UBQLN1 affects degradation of RTKs (Figure 14) 
These set of experiments were performed to test for role of UBQLN1 in 
degradation of IGF1R and EGFR. A549 cells were transfected with respective 
siRNA (siUBQLN1 or siNT) (Figure 14). 48 hours post-transfection, cells were 
incubated with either a proteasomal (MG132) or lysosomal inhibitor (NH4Cl) or 
both for an hour prior to stimulation with ligand IGF1 (50ng/ml) or EGF (10ng/ml). 
Therefore, in all, there were 5 experimental conditions as observed in the figure. 
Cells were harvested (6 hours after IGF1 stimulation or 3 hours after EGF 
stimulation) and analyzed by Western Blot. In the absence of lysosomal and 
proteasomal inhibitors, our results were consistent with our previous data. In 
UBQLN1 deficient cells, we observed decreased expression of total IGF1R and 
EGFR while phosphorylated IGF1R and EGFR levels were increased when 
stimulated with respective ligands. Presence of MG132 and NH4Cl, rescued 
some amount of total receptor levels otherwise degraded in the absence of 
UBQLN1 while stabilized phosphorylated IGF1R and EGFR in UBQLN1 deficient 
cells compared to control. These data imply that loss of UBQLN1 accelerates 
degradation of non-phosphorylated IGF1R and EGFR and therefore resulting in 
higher expression of phosphorylated form of the 2 receptors. It also appears that 
in A549 cells, UBQLN1 may be essential for lysosomal degradation of 
phosphorylated IGF1R as loss of UBQLN1 almost completely prevents its 
degradation via this pathway. Under these experimental conditions, proteasomal 
and lysosomal pathways degrade EGFR equally and UBQLN1 may play an 










Figure 14.1: Loss of UBQLN1 affects degradation of IGF1R 
These experiments were performed in A549 cells following siRNA 
mediated knock down of UBQLN1 (siU1). 48 hours post siRNA 
transfections; cells were exposed to 5 different conditions in the presence 
of cycloheximide. Serum starvation (SS) for 12 hours, SS for 12h and 
stimulation by 50ng/ml recombinant IGF1 for 6 h, addition of MG132 an 
hour prior to ligand stimulation, addition of NH4Cl, a lysosomal inhibitor an 
hour prior to stimulation and addition of both inhibitors. There is 
decreased total IGF1R in siU1 lanes in all conditions. MG132 and NH4Cl, 
both rescue IGF1R from degradation implying that under these 
experimental conditions, IGF1R is degraded via both routes. Higher 
phosphorylated receptor levels are observed consistently across all siU1 
cells in all conditions indicating that loss of UBQLN1 prevents 
dephosphorylation of IGF1R and stabilizes the active receptor. In 
addition, use of MG132 and NH4Cl further stabilize the active receptor. In 
conclusion, loss of UBQLN1 accelerates degradation of non-
phosphorylated IGF1R while stabilizes the phosphorylated form. 










Figure 14.2: Loss of UBQLN1 affects degradation of EGFR 
These experiments were performed in A549 cells following siRNA 
mediated knock down of UBQLN1 (siU1). 48 hours post siRNA 
transfections; cells were exposed to 5 different conditions in the 
presence of cycloheximide. Serum starvation (SS) for 12 hours, SS for 
12h and stimulation by 50ng/ml recombinant EGF for 3 hours, addition 
of MG132 an hour prior to ligand stimulation, addition of NH4Cl, a 
lysosomal inhibitor an hour prior to stimulation and addition of both 
inhibitors. There is decreased total EGFR in siU1 lanes in all conditions. 
MG132 and NH4Cl, both rescue EGFR from degradation implying that 
under these experimental conditions, EGFR is degraded via both 
routes. Higher phosphorylated receptor levels are observed consistently 
across all siU1 cells in all conditions indicating that loss of UBQLN1 
prevents dephosphorylation of EGFR and stabilizes the active receptor. 
In addition, use of MG132 and NH4Cl further stabilize the active 
receptor. In conclusion, loss of UBQLN1 accelerates degradation of 
non-phosphorylated IGF1R while stabilizes the phosphorylated form. 





IGF1R degradation assay  (Figure 15) 
Our data showed that UBQLN1 regulates steady state expression and 
degradation of IGF1R and EGFR. UBQLN1 deficient cells have lower mRNA and 
protein levels of IGF1R and EGFR, but higher expression of phosphorylated form 
of the receptor 6 and 3 hours post stimulation with ligand. To test if the increased 
expression phosphorylated receptor was sustained at longer time points, a 
degradation assay of the receptor was performed. In this experiment, A549 cells 
were cultured in complete media and transfected with siRNA for UBQLN1 or 
control. Cycloheximide (20uM) was added to the media to prevent biosynthesis 
of new protein levels. The ligand IGF1 (50ng/ml) was spiked into the serum free 
media after 60 minutes exposure of cells to cycloheximide and followed for 5 
different time points: 0h, 6h, 12h, 18h, 27h. At the end of each time point, cells 
were harvested, lysed and analyzed by Western Blot to test for protein 
expression. For every time point, expression of total IGF1R was decreased in 
UBQLN1 deficient cells and the differences became more apparent with longer 
time points. Phosphorylated receptor was detected only in IGF1 stimulated cells 
with highest expression at 6h and decreased phosphorylation at longer time 
points. Most importantly, phosphorylated receptor levels were detected even at 
27 hours post ligand stimulation. IGF1R activation stimulates PI3K/AKT pathway 
and expression of AKT was tested for effects of UBQLN1 knockdown on this 
pathway. A similar trend was observed for both IGF1R and AKT proteins such 
that total protein level expression in UBQLN1 deficient cells were decreased 
while the phosphorylated protein levels were increased at 0h in absence of IGF1 
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stimulation and differences in protein expression were more pronounced post 
ligand stimulation even at 27 hours. In conclusion, IGF1R protein was not fully 
degraded even at the longest time point chosen for this experiment (27 hours). 
However, IGF1R half-life studies have not been published in lung 
adenocarcinoma cell lines before and therefore this may not necessarily be an 




























Figure 15: IGF1R degradation assay 
A549 cells were transfected with siRNA (NT: non targeting control, U1 
and U1_2: UBQLN1). 48 hours post transfection, cells were serum 
starved for 12 hours and exposed to translational inhibitor 
cycloheximide before stimulating with ligand IGF1 and chased for the 
following time points:0h, 6h, 12h, 18, 27h. Total IGF1R levels were 
decreased in UBQLN1 knock down cells at all time points and results 
are more pronounced at later time points.  Phosphorylated IGF1R 
levels were undetectable 0h without ligand stimulation and at every 
other time point,  in complete and serum deficient media, however post 
stimulation with IGF1, the ratio of phosphorylated to total IGF1R levels 
was greatly increased in siUBQLN1 cells (1.46, 2.10 vs. 1.05) 






CHAPTER 4: DISCUSSION 
The role of Ubiquilin proteins is largely studied in the field neurodegenerative 
disorders and is slowly emerging in the field of cancer. We have demonstrated 
role of UBQLN1 in lung cancer and how UBQLN1 regulates expression and 
activity of receptor tyrosine kinases like IGF1R and EGFR. Our lab has 
previously shown that UBQLN1 is lost and under-expressed in lung 
adenocarcinomas cell lines and samples [1] and cells that have loss of UBQLN1 
develop clonogenic potential and migratory and invasive properties [4].  
 
We have identified an interaction between UBQLN1 and IGF1R and INSR. Some 
mutations in UBL, UBA and STI domains of UBQLN1 led to loss of interaction 
with IGF1R. UBQLN1 interacts with and regulates expression and activity of 
IGF1R in lung cell lines. When UBQLN1 is lost, there is decreased overall 
expression of IGF1 receptors. Similarly, loss of UBQLN1 also leads to a 
decrease in expression of EGFR, despite only weakly interacting with it, which 
indicates that UBQLN1 regulates expression of receptor tyrosine kinases 
independent of interaction. Research studying the role of UBQLN1 in receptor 
trafficking have only been conducted in neurons where expression of UBQLN1 
stabilizes cell surface levels of GABAA receptors [47] and upregulates nicotinic 
acetylcholine receptors [20]. Radioligand binding assays confirmed that 
decreased total receptor levels in UBQLN1 deficient cells also reflected as 
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decreased number of cell surface IGF1R in these cells. Despite fewer receptors 
being activated in UBQLN1 deficient cells, there is an increased ratio of 
phosphorylated to total receptor levels. Loss of UBQLN1 leads to higher levels of 
phosphorylated IGF1R, EGFR and AKT protein levels. Experiments in a lung 
adenocarcinoma cell line also showed that the higher expression of active IGF1R 
is also sustained at the longest time point tested–27 hours after ligand 
stimulation.  Decreased levels of IGF1R and EGFR in UBQLN1 deficient cells 
can be a result of decreased biosynthesis of the protein or increased turnover or 
a variety of post-translational modifications or a combination of all. UBQLN1 
deficient A549 cells showed 50% decrease in transcript levels of IGF1R and 30% 
decrease in EGFR levels demonstrating there is decreased biosynthesis of the 
RTKs. One of UBQLN1’s well-known functions is facilitating degradation of 
proteins [18, 27, 48] When tested for degradation of the receptor, loss of 
UBQLN1 stabilized the phosphorylated receptor and accelerated degradation of 
the non-phosphorylated receptor. This suggests that when UBQLN1 is present, it 
directly or indirectly, mediates degradation of phosphorylated IGF1R and EGFR 
and plays an important role in RTK trafficking and turnover. Mechanisms 
underlying these phenomena are not currently known but we suggest that higher 
levels and/or longer duration of a continuously active protein can contribute to 
initiation and/or progression of transforming events in cells.  
Ubiquitination is a crucial regulatory process in protein signaling and turnover. 
Ubiquitination of proteins is a multi-step process such that E1 and E2 ligases 
recruit protein specific E3 ligases to load ubiquitin molecules on it. Three E3 
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ligases have been identified to ubiquitinate IGF1R namely Mdm2[38], Nedd4[39], 
and c-Cbl[40]. Mdm2 mono-ubiquitinates IGF1R at multiple sites on the receptor, 
Nedd4 polyubiquitinates with K63 type chains and c-Cbl polyubiquitinates with 
K48 type chains. K48 poly-ubiquitination signals proteins towards the 
proteasome for degradation while K63 mono- and poly-ubiquitination signals for 
interactions with proteins for other cellular processes [30]. Normally, activated 
IGF1R and EGFR are internalized by endocytosis and subsequently 
downregulated by lysosomes or ubiquitin-proteasome system or recycled back to 
the plasma membrane thus tightly regulating the duration and intensity of 
downstream signaling events [37]. Studies have shown that mutations in proteins 
(ex: c-Cbl) that control RTK (ex: c-MET) trafficking and turnover can cause this 
regulation to be lost such that it leads to persistent activity of the receptor even in 
the absence of receptor overexpression or activating oncogenic mutations [49]. 
Based on data on UBQLN1’s interaction with ubiquitinated proteins [6, 18], it is 
most likely that UBQLN1 acts as an adaptor protein aiding in ubiquitination of the 
phosphorylated receptor. There is no data currently on whether Ubiquilin1 binds 
E3 ligases. However, UBQLN1 binds ubiquitin through its UBA domain and may 
control type of ubiquitination in coordination with other proteins. As stabilization 
of the phosphorylated RTK is a hallmark finding of loss of UBQLN1 in lung 
cancer cell lines, we hypothesize that normally UBQLN1 facilitates K48 poly-
ubiquitination of non-phosphorylated receptor and signals for its degradation. In 
absence of UBQLN1, the phosphorylated RTK is unable to get degraded leading 
to its stabilization and continuous stimulation of downstream signaling pathways. 
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An alternate theory is that UBQLN1 may be required for normal activity of 
phosphatases that act on RTK’s. Timely downregulation of phosphorylated 
IGF1R and EGFR may be delayed in absence of UBQLN1, leading to stabilized 
activity of the phosphorylated RTK. The phosphatase protein PTP1B negatively 
regulates IGF1R phosphorylation in a ligand dependent manner[50]. Another 
phosphatase SHP2 associates simultaneously with phospho-tyrosines on IGF1R 
and SH2 domains and directly dephosphorylates IGF1R. An adaptor protein, 
SHPS2 is critical for recruitment of the phosphatase to the plasma membrane. 
An integrin protein αVβ3 acts via this phosphatase SHP2 to decrease 
phosphorylation of IGF1R [51]. Ubiquilin1 was originally discovered as an integrin 
associated protein [2] and through its action on integrins may control SHP2 
phosphatases activity.  
Overall, UBQLN1 regulates activity of IGF1R and EGFR and in cancers that have 
loss of UBQLN1, dysregulation of this activity may contribute to initiation and 
progression of tumorigenesis and it may also contribute to other pathologies 
associated with RTK aberrations. While RTK’s has been shown to be a logical 
and valid target for many cancers including lung adenocarcinoma, targeting 
these receptors has not proven to be very successful in the long run. Possible 
reasons for failure include the complexity of the RTK system, parallel growth and 
survival pathways and lack of patient selection biomarkers. A variety of 
mechanisms may confer intrinsic or acquired resistance, highlighting the need for 
understanding the regulation of IGF1R in greater detail. Regulation of activity of 
receptors after ligand binding/activation can often be overlooked when 
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developing therapeutics against targeted receptor. We have observed that 
UQBLN1 regulates IGF1R activity such that lung adenocarcinoma cell lines that 
have loss of UBQLN1 have higher activity of the RTK. UBQLN1 loss in tumors 
can act as a biomarker for patient selection for treating with receptor tyrosine 
kinase pathway inhibitors. In conclusion, UBQLN1 plays a role in regulating RTK 
expression and activity and studying its mechanism of action is warranted and 
promising as a novel therapeutic approach in pathologies involving receptor 
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